Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024)
Zoetis (ZTS) posted quarterly Liabilities from Discontinued Operations of 26000000.0 for Q3 2024, up 4.0% quarter-over-quarter from 25000000.0 in Q2 2024.
Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024) Analysis & Trends
Zoetis (ZTS) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 26000000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 26000000.0; the TTM figure through Sep 2024 stood at 26000000.0 (changed N/A YoY), while the FY2015 annual figure was 4000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations advanced to 26000000.0 in Q3 2024 per ZTS's latest filing, from 25000000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 26000000.0 in Q3 2024 and bottomed at 25000000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 26.00 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 25.00 Mn |
| Jun 30, 2024 | 25.00 Mn |
| Dec 31, 2015 | 4.00 Mn |
| Dec 31, 2015 | 4.00 Mn |